scholarly journals Potentiation of neuronal ATP-sensitive potassium channels as a novel target for neuropathic pain

2015 ◽  
Vol 146 (1) ◽  
pp. 10-15
Author(s):  
Takashi Kawano
2017 ◽  
Vol 121 ◽  
pp. 49-59 ◽  
Author(s):  
Lorenzo Di Cesare Mannelli ◽  
Elena Lucarini ◽  
Laura Micheli ◽  
Ilaria Mosca ◽  
Paolo Ambrosino ◽  
...  

2013 ◽  
Vol 57 ◽  
pp. 1-9 ◽  
Author(s):  
Sarah L. Pollema-Mays ◽  
Maria Virginia Centeno ◽  
Crystle J. Ashford ◽  
A Vania Apkarian ◽  
Marco Martina

2014 ◽  
Vol 125 ◽  
pp. S229 ◽  
Author(s):  
S. Jaeaeskelaeinen ◽  
P. Lindholm ◽  
S. Lamusuo ◽  
A. Lahti ◽  
U. Pesonen ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Roberta Lattanzi ◽  
Daniela Maftei ◽  
Veronica Marconi ◽  
Fulvio Florenzano ◽  
Silvia Franchi ◽  
...  

The new chemokine Prokineticin 2 (PROK2) and its receptors (PKR1and PKR2) have a role in inflammatory pain and immunomodulation. Here we identified PROK2 as a critical mediator of neuropathic pain in the chronic constriction injury (CCI) of the sciatic nerve in mice and demonstrated that blocking the prokineticin receptors with two PKR1-preferring antagonists (PC1 and PC7) reduces pain and nerve damage. PROK2 mRNA expression was upregulated in the injured nerve since day 3 post injury (dpi) and in the ipsilateral DRG since 6 dpi. PROK2 protein overexpression was evident in Schwann Cells, infiltrating macrophages and axons in the peripheral nerve and in the neuronal bodies and some satellite cells in the DRG. Therapeutic treatment of neuropathic mice with the PKR-antagonist, PC1, impaired the PROK2 upregulation and signalling. This fact, besides alleviating pain, brought down the burden of proinflammatory cytokines in the damaged nerve and prompted an anti-inflammatory repair program. Such a treatment also reduced intraneural oedema and axon degeneration as demonstrated by the physiological skin innervation and thickness conserved in CCI-PC1 mice. These findings suggest that PROK2 plays a crucial role in neuropathic pain and might represent a novel target of treatment for this disease.


2003 ◽  
Vol 138 (5) ◽  
pp. 751-756 ◽  
Author(s):  
A Ciruela ◽  
A K Dixon ◽  
S Bramwell ◽  
M I Gonzalez ◽  
R D Pinnock ◽  
...  

Pain ◽  
2011 ◽  
Vol 152 (11) ◽  
pp. 2605-2615 ◽  
Author(s):  
Xue-Feng Wu ◽  
Wen-Tao Liu ◽  
Yue-Peng Liu ◽  
Zhi-Jiang Huang ◽  
Yan-Kai Zhang ◽  
...  

Pain ◽  
2016 ◽  
Vol 157 ◽  
pp. S7-S14 ◽  
Author(s):  
Jérôme Busserolles ◽  
Christoforos Tsantoulas ◽  
Alain Eschalier ◽  
José A. López García

2018 ◽  
Author(s):  
Salim Megat ◽  
Pradipta R. Ray ◽  
Jamie K. Moy ◽  
Tzu-Fang Lou ◽  
Paulino Barragan-Iglesias ◽  
...  

AbstractPain sensing neurons, nociceptors, are key drivers of neuropathic pain. We used translating ribosome affinity purification (TRAP) to comprehensively characterize up-and down-regulated mRNA translation in Scn10a-positive nociceptors in chemotherapy-induced neuropathic pain. We provide evidence that an underlying mechanism driving these changes in gene expression is a sustained mTORC1 activation driven by MNK1-eIF4E signaling. RagA, a GTPase controlling mTORC1 activity, is identified as a novel target of MNK1-eIF4E signaling, demonstrating a new link between these distinct signaling pathways. Neuropathic pain and RagA translation are strongly attenuated by genetic ablation of eIF4E phosphorylation, MNK1 elimination or treatment with the MNK inhibitor eFT508. We reveal a novel translational circuit for the genesis of neuropathic pain with important implications for next generation neuropathic pain therapeutics.One Sentence SummaryCell-specific sequencing of translating mRNAs elucidates signaling pathology that can be targeted to reverse neuropathic pain


Sign in / Sign up

Export Citation Format

Share Document